Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erlotinib in Advanced Pancreatic Cancer

Erlotinib in Advanced Pancreatic Cancer Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. While the future of erlotinib plus gemcitabine in the treatment of pancreatic cancer may continue to be as a ‘sometimes used’ A Viewpoint by Peter Kozuch option, other strategies to optimally incorporate erlotinib into the 1 St Luke’s-Roosevelt Hospital Center, New York, New care of pancreatic cancer patients should be evaluated. One way to York, USA optimize the use of erlotinib would be to identify and validate 2 Continuum Cancer Centers of New York, New York, New molecular profiles that predict for drug sensitivity, a strategy that York, USA is also being evaluated in NSCLC and for the epidermal growth 3 College of Physicians and Surgeons, Columbia University factor receptor (EGFR) tyrosine kinase inhibitor gefitinib. Devel- Medical Center, New York, New York, USA opment of other erlotinib-containing combinations is another theme that warrants investigation. In fact, erlotinib is currently Because of its highly metastatic potential and relative chemo- undergoing phase II evaluation in combination with gemcitabine therapy resistance, pancreatic cancer remains one of the most plus the anti-vascular endothelial growth factor monoclonal an- difficult human malignancies to treat. Gemcitabine, due http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Erlotinib in Advanced Pancreatic Cancer

American Journal of Cancer , Volume 5 (1) – Aug 10, 2012

Erlotinib in Advanced Pancreatic Cancer

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. While the future of erlotinib plus gemcitabine in the treatment of pancreatic cancer may continue to be as a ‘sometimes used’ A Viewpoint by Peter Kozuch option, other strategies to optimally incorporate erlotinib into the 1 St Luke’s-Roosevelt Hospital Center, New York, New care of pancreatic cancer patients should be evaluated. One...
Loading next page...
 
/lp/springer-journals/erlotinib-in-advanced-pancreatic-cancer-GeryfmExp5
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00008
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. While the future of erlotinib plus gemcitabine in the treatment of pancreatic cancer may continue to be as a ‘sometimes used’ A Viewpoint by Peter Kozuch option, other strategies to optimally incorporate erlotinib into the 1 St Luke’s-Roosevelt Hospital Center, New York, New care of pancreatic cancer patients should be evaluated. One way to York, USA optimize the use of erlotinib would be to identify and validate 2 Continuum Cancer Centers of New York, New York, New molecular profiles that predict for drug sensitivity, a strategy that York, USA is also being evaluated in NSCLC and for the epidermal growth 3 College of Physicians and Surgeons, Columbia University factor receptor (EGFR) tyrosine kinase inhibitor gefitinib. Devel- Medical Center, New York, New York, USA opment of other erlotinib-containing combinations is another theme that warrants investigation. In fact, erlotinib is currently Because of its highly metastatic potential and relative chemo- undergoing phase II evaluation in combination with gemcitabine therapy resistance, pancreatic cancer remains one of the most plus the anti-vascular endothelial growth factor monoclonal an- difficult human malignancies to treat. Gemcitabine, due

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.